The anti-interleukin agent romilkimab showed significant benefits on skin fibrosis among patients with systemic sclerosis in a phase II trial, researchers reported. At week 24, the least squares mean ...

Patients with SSc were linked to an increased risk for hematological malignancies, specifically B-cell malignancies.

Telitacicept, a dual inhibitor of the cytokines B-lymphocyte stimulator and a proliferation-inducing ligand, showed efficacy ...

Nutritional issues such as ARFID are highly prevalent among patients with SSc and can lead to poor outcomes and other ...

SPRINGFIELD, Ohio — Tyeesha Ferguson fears her 28-year-old son will kill or be killed. "That's what I'm trying to avoid," said Ferguson, who still calls Quincy Jackson III her baby. She remembers a ...

Objectives The European Alliance of Associations for Rheumatology (EULAR) recommendations for the management of systemic lupus erythematosus (SLE) and lupus nephritis provide important guidance for ...